<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927979</url>
  </required_header>
  <id_info>
    <org_study_id>CMC090074CTIL</org_study_id>
    <secondary_id>PSDR</secondary_id>
    <nct_id>NCT00927979</nct_id>
  </id_info>
  <brief_title>Pain Relief by Intra-Peritoneal Nebulization of Ropivacaine Under Remifentanil Anesthesia for Gynecological Laparoscopy</brief_title>
  <acronym>PSDR</acronym>
  <official_title>Phase 3 Prospective, Randomized, Controlled and Double-blinded Second Trial on Pain Relief by Continuous Intra-peritoneal Nebulization of Ropivacaine Under Remifentanil Anesthesia, During Gynecological Laparoscopic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carmel Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carmel Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In our prospective, randomized, placebo controlled and double-blinded study we will study the
      efficacy of intraperitoneal ropivacaine nebulization on pain relief during gynecologic
      laparoscopic surgery. This is a second steady with protocol of general anesthesia used of
      Remifentanil.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Outcome Measures :

        -  VAS score

        -  Use of analgesics during operation and postoperative period
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Score (VAS)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Use of Analgesics</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Gynecological Laparoscopy</condition>
  <arm_group>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Water for injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 mLRopivacaine 1%</intervention_name>
    <description>Intraperitoneal nebulization of 10 mL Ropivacaine 1%</description>
    <arm_group_label>Ropivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Water for injection</intervention_name>
    <description>Intraperitoneal nebulization of 10 mL water for injection</description>
    <arm_group_label>Water for injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 mL Ropivacaine 1%</intervention_name>
    <description>Intraperitoneal nebulization of 10 mL Ropivacaine 1%</description>
    <arm_group_label>Ropivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective gynecological laparoscopic surgery including unilateral or bilateral
             salpingo-oophorectomy or ovarian cystectomy

          -  Patient not participating in other medical study at present or during the last 30 days

          -  Patient is capable of reading, understanding and signing on an informed consent

          -  Age 18 years and above

          -  ASA physical status grade 1-2

        Exclusion Criteria:

          -  Allergy to ropivacaine or other local anesthetics or other medications listed in the
             protocol

          -  Acute pelvic inflammatory disease

          -  Coumadin or aspirin treatment

          -  Significant arrythmias

          -  Analgesic treatment for chronic pain

          -  BMI&gt;35
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2009</study_first_submitted>
  <study_first_submitted_qc>June 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <last_update_submitted>June 26, 2011</last_update_submitted>
  <last_update_submitted_qc>June 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Ostrovsky Ludmila</name_title>
    <organization>Carmel Medical Center</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

